In defending against a lawsuit brought by unhappy shareholders, the biotech firm Amgen is trying to force a newsletter reporter to disclose how he learned about negative clinical trial results for one of the firm's products, Ed Silverman writes: "As Erik Gordon of the Ross School of Business at the University of Michigan notes, the newsletter 'got dragged in because the shareholders are quoting it saying there was important information people weren’t aware of.'"
June 15, 2015
.png)
